Tech Company Financing Transactions
InSilico Medicine Funding Round
InSilico Medicine, operating out of Hong Kong, received $110 million from Value Partners and private investors.
Transaction Overview
Company Name
Announced On
3/13/2025
Transaction Type
Venture Equity
Amount
$110,000,000
Round
Series E
Investors
Value Partners (Lead Investor)
Proceeds Purpose
The company intends to use the fund to advance innovative drug pipeline and AI platform developments.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Core Building 1 1 Science Park East Ave.Hong Kong Science Pa 307A
Hong Kong, 00000
Hong Kong
Hong Kong, 00000
Hong Kong
Phone
Undisclosed
Website
Email Address
Overview
Our Mission is to extend healthy longevity through innovative AI solutions for drug discovery and aging research. We aspire to be a leader in the field of deep learning for drug discovery, personalized healthcare, and anti-aging interventions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alex Zhavoronkov
Chief Operating Officer
Qingsong Zhu
Chief Scientific Officer
Jimmy Lin
Chief Technical Officer
Alex Zhebrak
President
Alex Aliper
Browse more venture capital transactions:
Prev: 3/13/2025: Rangsons Aerospace venture capital transaction
Next: 3/13/2025: Alloyed venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs